DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Given Consensus Recommendation of "Hold" by Analysts

Key Points

• Analysts have assigned DENTSPLY SIRONA a consensus rating of Hold from 14 analysts (3 sell, 8 hold, 3 buy) with an average 12‑month price target of $13.91.
• The company slightly missed quarterly EPS ($0.27 vs. $0.28) while beating revenue ($961M vs. $926.4M), and set FY2026 guidance of 1.400–1.500 EPS versus analysts' expectation of about 1.43.
• Shares opened at $11.48 (market cap ~$2.3B, 52‑week range $9.85–$17.18); insiders purchased roughly 70,000 shares last quarter while institutional investors own about 95.7% of the stock.

Shares of DENTSPLY SIRONA Inc. (NASDAQ:XRAY - Get Free Report) have been assigned a consensus rating of "Hold" from the fourteen analysts that are presently covering the firm, Marketbeat.com reports. Three equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and three have given a buy rating to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $13.9091.

A number of research analysts have recently commented on XRAY shares. Barrington Research increased their target price on shares of DENTSPLY SIRONA from $14.00 to $17.00 and gave the stock an "outperform" rating in a report on Monday, March 2nd. UBS Group dropped their target price on shares of DENTSPLY SIRONA from $17.00 to $16.00 and set a "buy" rating for the company in a report on Tuesday, February 3rd. Robert W. Baird increased their target price on shares of DENTSPLY SIRONA from $12.00 to $14.00 and gave the stock a "neutral" rating in a report on Friday, February 27th. Zacks Research raised shares of DENTSPLY SIRONA from a "strong sell" rating to a "hold" rating in a report on Monday, March 2nd. Finally, Citigroup started coverage on shares of DENTSPLY SIRONA in a report on Wednesday, April 15th. They issued a "sell" rating and a $10.00 target price for the company.

DENTSPLY SIRONA Stock Down 2.5%

XRAY stock opened at $11.48 on Thursday. The stock has a market capitalization of $2.30 billion, a P/E ratio of -3.83, a price-to-earnings-growth ratio of 1.41 and a beta of 0.99. The company has a current ratio of 1.51, a quick ratio of 1.03 and a debt-to-equity ratio of 1.50. DENTSPLY SIRONA has a 12 month low of $9.85 and a 12 month high of $17.18. The firm has a 50-day moving average price of $12.18 and a 200-day moving average price of $12.04.

DENTSPLY SIRONA (NASDAQ:XRAY - Get Free Report) last posted its earnings results on Thursday, February 26th. The medical instruments supplier reported $0.27 EPS for the quarter, missing analysts' consensus estimates of $0.28 by ($0.01). The company had revenue of $961.00 million during the quarter, compared to the consensus estimate of $926.40 million. DENTSPLY SIRONA had a positive return on equity of 18.85% and a negative net margin of 16.25%.The firm's revenue was up 6.2% compared to the same quarter last year. During the same period last year, the company posted $0.26 EPS. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. As a group, equities research analysts anticipate that DENTSPLY SIRONA will post 1.43 EPS for the current fiscal year.

Insider Buying and Selling

In other DENTSPLY SIRONA news, Director James D. Forbes acquired 5,000 shares of the company's stock in a transaction that occurred on Monday, March 9th. The stock was acquired at an average price of $12.48 per share, for a total transaction of $62,400.00. Following the acquisition, the director directly owned 10,000 shares in the company, valued at $124,800. This represents a 100.00% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Gregory T. Lucier acquired 27,555 shares of the company's stock in a transaction that occurred on Monday, March 2nd. The stock was acquired at an average price of $14.24 per share, with a total value of $392,383.20. Following the acquisition, the director owned 27,555 shares in the company, valued at $392,383.20. The trade was a ∞ increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last quarter, insiders purchased 70,000 shares of company stock valued at $956,437. 0.52% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in DENTSPLY SIRONA in the 1st quarter valued at approximately $26,000. Eurizon Capital SGR S.p.A. bought a new position in DENTSPLY SIRONA in the 4th quarter valued at approximately $26,000. Caitong International Asset Management Co. Ltd raised its holdings in DENTSPLY SIRONA by 337.9% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 2,750 shares of the medical instruments supplier's stock valued at $35,000 after buying an additional 2,122 shares during the last quarter. Huntington National Bank raised its holdings in DENTSPLY SIRONA by 292.9% in the 3rd quarter. Huntington National Bank now owns 2,786 shares of the medical instruments supplier's stock valued at $35,000 after buying an additional 2,077 shares during the last quarter. Finally, True Wealth Design LLC raised its holdings in DENTSPLY SIRONA by 49.7% in the 3rd quarter. True Wealth Design LLC now owns 3,557 shares of the medical instruments supplier's stock valued at $45,000 after buying an additional 1,181 shares during the last quarter. Institutional investors own 95.70% of the company's stock.

DENTSPLY SIRONA Company Profile

Dentsply Sirona Inc NASDAQ: XRAY is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company's product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.